摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S,2R,3R,4R,6R)-4-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl)-2-hydroxy-6-methylcyclohexane-1,3-diyl diacetate | 1232680-38-4

中文名称
——
中文别名
——
英文名称
(1S,2R,3R,4R,6R)-4-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl)-2-hydroxy-6-methylcyclohexane-1,3-diyl diacetate
英文别名
[(1S,2R,3R,4R,6R)-3-acetyloxy-4-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-2-hydroxy-6-methylcyclohexyl] acetate
(1S,2R,3R,4R,6R)-4-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl)-2-hydroxy-6-methylcyclohexane-1,3-diyl diacetate化学式
CAS
1232680-38-4
化学式
C26H26O11
mdl
——
分子量
514.486
InChiKey
WADXCMSONJVPKX-LTBIHHBXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    37
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    169
  • 氢给体数:
    4
  • 氢受体数:
    11

反应信息

  • 作为产物:
    描述:
    (1S,2R,3R,4R,6R)-4-(5,7-bis(benzyloxy)-2-(4-benzyloxyphenyl)-4-oxo-4H-chromen-3-yl)-2-hydroxy-6-methylcyclohexane-1,3-diyl diacetate 在 palladium 10% on activated carbon 、 氢气 作用下, 以 四氢呋喃乙醇 为溶剂, 以63%的产率得到(1S,2R,3R,4R,6R)-4-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl)-2-hydroxy-6-methylcyclohexane-1,3-diyl diacetate
    参考文献:
    名称:
    SL0101 Carbasugar 类似物的合成:Carbasugars 通过 Pd 催化的环醇化和环醇化后转化
    摘要:
    已经开发了立体选择性合成 5a-carbasugars 的一般方法。该路线模拟了我们对碳水化合物的钯催化糖基化/糖基化后方法,因为它还利用高度区域和立体特异性钯催化烯丙基化和糖基化后反应序列来安装d - 或l -环多醇。该环醇化/环醇化后序列用于对映选择性合成 SL0101 的环醇类似物、其d-糖对映异构体以及几种乙酰化模式类似物。
    DOI:
    10.1021/ol101009q
点击查看最新优质反应信息

文献信息

  • SYNTHESIS AND IDENTIFICATION OF NOVEL RSK-SPECIFIC INHIBITORS
    申请人:Hecht Sidney M.
    公开号:US20120245112A1
    公开(公告)日:2012-09-27
    A composition comprising an SL0101 [kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell.
  • US9040673B2
    申请人:——
    公开号:US9040673B2
    公开(公告)日:2015-05-26
  • Synthesis of SL0101 Carbasugar Analogues: Carbasugars via Pd-Catalyzed Cyclitolization and Post-Cyclitolization Transformations
    作者:Mingde Shan、George A. O’Doherty
    DOI:10.1021/ol101009q
    日期:2010.7.2
    A general approach to the stereoselective synthesis of 5a-carbasugars has been developed. The route mimics our palladium-catalyzed glycosylation/postglycosylation approach to carbohydrates in that it also utilizes a highly regio- and stereospecific palladium-catalyzed allylation and postglycosylation reaction sequence for the installation of either d- or l-cyclitols. This cyclitolization/postcyclitolization
    已经开发了立体选择性合成 5a-carbasugars 的一般方法。该路线模拟了我们对碳水化合物的钯催化糖基化/糖基化后方法,因为它还利用高度区域和立体特异性钯催化烯丙基化和糖基化后反应序列来安装d - 或l -环多醇。该环醇化/环醇化后序列用于对映选择性合成 SL0101 的环醇类似物、其d-糖对映异构体以及几种乙酰化模式类似物。
查看更多